Background Medication-related osteonecrosis of the jaw (MRONJ), which was first reported
as bisphosphonate-related osteonecrosis of the jaw (BRONJ) in bisphosphonate users, is a …

Background Antiresorptive agents such as bisphosphonates and denosumab, as well as
angiogenesis inhibitors, may induce medication-related osteonecrosis of the jaw (MRONJ) …

Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
affecting patients with cancer and patients with osteoporosis who have been treated with …

Conditions such as congenital anomalies, cancers, and trauma can all result in devastating
deficits of bone in the craniofacial skeleton. This can lead to significant alteration in function …

Since the initial description of medication‐related osteonecrosis of the jaw (MRONJ) almost
two decades ago, the potential pathophysiology and risk factors have been elaborated on in …

Osteonecrosis of the jaws (ONJ) is a complication of antiresorptive medications, such as
denosumab or bisphosphonates, prescribed to patients with bone malignancy or …

Medication‐related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse effect of
antiresorptive medications administered for control of osseous malignancy, osteoporosis, or …

Although osteonecrosis of the jaws (ONJ), a serious complication of antiresorptive
medications, was reported a decade ago, the exact mechanisms of disease pathophysiology …

The precise pathoetiology and effective treatment strategies for bisphosphonate‐related
osteonecrosis of the jaw (BRONJ) remain unknown. Transplantation of noncultured stromal …

Objective To assess the outcomes of several rodent animal models for studying tooth
extraction-related medication-related osteonecrosis of the jaw (MRONJ). Design After a …